Author

J. Rajadas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Organism:bacteria (other)· 1 Research Focus:phylogenetics / evolution· 1 Assay:proteomics· 1

Frequent Co-Authors

H.-H. S. Potula· 2 shared A. Frymoyer· 1 shared A. Hargil· 1 shared A. L. Sapiro· 1 shared A. V. Malkovskiy· 1 shared B. Lee· 1 shared B. W. Zaro· 1 shared E. E. Bastounis· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H.-H. S. Potula

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

P66 is a bacterial mimic of CD47 that binds the anti-phagocytic receptor SIRPα and facilitates macrophage evasion by Borrelia burgdorferi

M. C. Tal, P. S. Hansen, H. A. Ogasawara, Q. Feng, R. F. Volk, B. Lee, S. E. Casebeer, G. S. Blacker, M. Shoham, S. D. Galloway, A. L. Sapiro, L.-B. T. Dulgeroff, T. Raveh, V. R. Pothineni, H.-H. S. Potula, , B. W. Zaro

This study identifies P66, a bacterial protein mimicking CD47, which binds SIRPα to evade macrophage phagocytosis, and shows its role in Lyme Disease pathogenesis.

bioRxiv · Apr 29, 2024 · PreprintImmunology

The pharmacokinetics and pharmacodynamics of 4-methylumbelliferone and its glucuronide metabolite in mice

N. Nagy, G. Kaber, N. Haddock, A. Hargil, J. Rajadas, S. Malhotra, M. Unger, A. Frymoyer, P. Bollyky

This paper investigates the pharmacokinetics and pharmacodynamics of 4-MU and its metabolite 4-MUG in mice, showing significant differences in exposure and bioavailability between administration routes.

bioRxiv · Aug 18, 2022 · PreprintPharmacology & Toxicology

Repurposing disulfiram (Tetraethylthiuram Disulfide) as a potential drug candidate against Borrelia burgdorferi in vitro and in vivo

H.-H. s. Potula, J. Shahryari, M. Inayathullah, A. V. Malkovskiy, K.-M. Kim, J. Rajadas

This study evaluates disulfiram's borreliacidal activity against Borrelia burgdorferi in vitro and in vivo, showing efficacy in eliminating the pathogen and reducing inflammation.

bioRxiv · Nov 15, 2019Microbiology